GSK2894512 1% Cream

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Dermatitis, AtopicPsoriasis

Phase 1

A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects

WithdrawnNCT03201978

GlaxoSmithKlinePsoriasis

Start: 2017-12-14End: 2018-05-15Updated: 2017-11-29

Phase 2

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

CompletedNCT02564042

GlaxoSmithKlinePsoriasis

Start: 2015-11-23End: 2016-10-05Updated: 2017-11-13

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

CompletedNCT02564055

GlaxoSmithKlineDermatitis, Atopic

Start: 2015-12-01End: 2017-01-12Updated: 2017-11-20

Phase 3

GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis

WithdrawnNCT03202004

GlaxoSmithKlinePsoriasis

Start: 2018-01-22End: 2018-09-28Updated: 2017-12-07

Related Papers

301 Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: 4-week maximal use trial

British Journal of Dermatology2023-01-251 citations